Clinical trial

Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLC

NCT02771314

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2016-08-02

PhasePHASE2

Study timeline

Study start (actual)2016-08-02Date precision: day

Registry last updated2019-02-22

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non Small Cell Lung Cancerunresolved

Interventions

AZD9291DRUG

Sponsors & collaborators

Hellenic Oncology Research Grouplead sponsor

Mapped research locations

AthensGreece8 ThessalonikiGreece3

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02771314 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.